Study guide

8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

Key Takeaways Explain This Topic AI

ARDS is characterized by acute non-cardiogenic pulmonary edema (PCWP ≤ 18 mmHg) with PaO2/FiO2 ≤ 300 mmHg and diffuse alveolar damage.

Low tidal volume ventilation (4-8 mL/kg predicted body weight) and plateau pressure ≤ 30 cmH2O significantly reduce mortality in ARDS.

Interstitial lung diseases manifest with a restrictive defect (FEV1/FVC > 0.70, TLC < 80%) and reduced DLCO due to alveolar-capillary membrane thickening.

Sarcoidosis presents with non-caseating granulomas, bilateral hilar lymphadenopathy, erythema nodosum, hypercalcemia, and elevated serum ACE levels.

Asbestosis features lower-lobe fibrosis and calcified pleural plaques, carrying a high risk of bronchogenic carcinoma (most common) and mesothelioma (most specific).

Last updated: July 2026

8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

Acute Respiratory Distress Syndrome (ARDS) represents severe, life-threatening non-cardiogenic pulmonary edema, while Interstitial Lung Diseases (ILD) comprise a heterogeneous group of restrictive parenchymal lung disorders. Mastering the Berlin criteria and mortality-reducing mechanical ventilation strategies for ARDS, alongside diagnostic hallmarks of sarcoidosis and occupational pneumoconioses, is high-yield for USMLE Step 2 CK.

  • Acute Respiratory Distress Syndrome (ARDS)
  • Berlin Diagnostic Definition Criteria

Acute Onset : Respiratory symptoms develop within 1 week of a known clinical insult or new/worsening pulmonary symptoms.

Bilateral Opacities : Diffuse bilateral pulmonary opacities on CXR or CT scan not fully explained by pleural effusions, lobar collapse, or lung nodules.

Non-Cardiogenic Origin : Respiratory failure NOT fully explained by cardiac failure or fluid overload . Confirmed by Pulmonary Capillary Wedge Pressure PCWP ≤ 18 mmHg or absence of left atrial hypertension on echocardiography.

Impaired Oxygenation (PaO2 / FiO2 ratio on PEEP ≥ 5 cmH2O) :

  • Mild ARDS : 200 < PaO2/FiO2 ≤ 300 mmHg
  • Moderate ARDS : 100 < PaO2/FiO2 ≤ 200 mmHg
  • Severe ARDS : PaO2/FiO2 ≤ 100 mmHg
  • Etiologies & Pathophysiology

Triggers : Sepsis (most common cause overall), severe pulmonary infection, severe trauma, massive blood transfusion (Transfusion-Related Acute Lung Injury - TRALI), acute pancreatitis, aspiration of gastric contents.

Pathophysiology : Uncontrolled inflammatory cascade → pulmonary capillary endothelial and alveolar epithelial cell damage → accumulation of neutrophils in microvasculature → release of proteases and reactive oxygen species → diffuse alveolar damage (DAD) → protein-rich fluid exudation into alveoli → formation of hyaline membranes → destruction of surfactant producing type II pneumocytes → microatelectasis and severe intrapulmonary right-to-left shunting (V/Q = 0, hypoxemia refractory to supplemental oxygen).

ARDS Mechanical Ventilation Principles (Mortality Benefit)

Standard mechanical ventilation strategies using large tidal volumes exacerbate lung injury through volutrauma (alveolar overdistension), barotrauma (high airway pressures), and atelectotrauma (repeated alveolar collapse and reopening). The ARDSNet trial established lung-protective ventilation principles that significantly improve survival.

Key Ventilator Management Principles

Low Tidal Volume Ventilation : Set initial tidal volume to 4–8 mL/kg of Predicted Body Weight (PBW) (calculated based on biological sex and height, NOT actual body weight!).

Limit Plateau Pressure : Maintain end-inspiratory plateau pressure Pplat ≤ 30 cmH2O .

Permissive Hypercapnia : Tolerating moderate hypercapnia and respiratory acidosis (pH down to 7.20–7.25) as an acceptable trade-off for maintaining lung-protective low tidal volumes.

High PEEP Titration : Titrate Positive End-Expiratory Pressure (PEEP) alongside FiO2 using PEEP/FiO2 tables to recruit collapsed alveoli, prevent end-expiratory alveolar collapse, and maintain oxygenation (target PaO2 55–80 mmHg or SpO2 88–95%).

Prone Positioning : Indicated for patients with severe ARDS ( PaO2/FiO2 < 150 ); performing prone positioning for ≥16 hours per day improves V/Q matching and significantly reduces mortality.

Interstitial Lung Diseases (ILD) Overview

Interstitial lung diseases (also termed diffuse parenchymal lung diseases) are characterized by inflammation and fibrosis of the alveolar septum and lung interstitium.

Clinical & Spirometric Pattern

Clinical Presentation : Progressive exertional dyspnea, dry non-productive cough, fine bilateral end-inspiratory "velcro-like" crackles on auscultation, and digital clubbing.

Pulmonary Function Testing (Restrictive Defect) :

  • FEV1/FVC Ratio : Normal or Increased ( > 0.70 )
  • Forced Vital Capacity (FVC) : Decreased (<80% predicted)
  • Total Lung Capacity (TLC) : Decreased (<80% predicted)
  • DLCO : Decreased (due to destruction and thickening of the alveolar-capillary interface)
  • Major Subtypes of Interstitial Lung Disease
  • 1. Idiopathic Pulmonary Fibrosis (IPF)

Progressive fibrotic lung disease typically affecting patients >60 years old.

HRCT Findings : Subpleural reticular opacities, traction bronchiectasis, and honeycombing (Usual Interstitial Pneumonia [UIP] pattern).

Pharmacotherapy : Antifibrotic agents ( Nintedanib , Pirfenidone ) slow the rate of FVC decline; definitive cure requires lung transplantation.

2. Sarcoidosis

Multisystem granulomatous disease predominantly affecting young African American women and individuals of Northern European descent.

Histology : Non-caseating granulomas composed of epithelioid histiocytes and multinucleated giant cells.

Clinical Features : Asymptomatic (incidental CXR finding), fatigue, low-grade fever, weight loss, anterior uveitis, erythema nodosum (tender red pretibial nodules), bell palsy, Heerfordt syndrome (uveitis, parotid gland enlargement, facial nerve palsy, fever).

Laboratory Findings : Elevated serum ACE levels , hypercalcemia and hypercalciuria (caused by extrarenal 1-α-hydroxylase production in granuloma macrophages → increased 1,25-dihydroxyvitamin D).

Chest Radiograph : Bilateral hilar lymphadenopathy with or without parenchymal reticular opacities.

Treatment : Oral Systemic Corticosteroids (prednisone) indicated for symptomatic patients or end-organ impairment (ocular, cardiac, neuro, or severe pulmonary involvement).

3. Occupational Pneumoconioses

Disorder Exposure History Imaging & Histology Findings Key USMLE Associations

Silicosis Sandblasting, quarrying, mining, masonry, glass cutting "Eggshell calcification" of hilar lymph nodes; upper lobe nodular opacities High risk of Tuberculosis (TB) infection (silica impairs macrophage phagolysosome fusion)

Asbestosis Shipyards, insulation, roofing, demolition, plumbing Pleural plaques (calcified diaphragmatic thickening); lower lobe fibrosis; Ferruginous bodies (golden-brown iron-coated dumbbell rods) Bronchogenic carcinoma (most common malignancy); Malignant Mesothelioma (most specific cancer)

Coal Worker's Coal mining Small nodular opacities in upper lobes Caplan syndrome (rheumatoid arthritis + pneumoconiosis nodules)

Berylliosis Aerospace, nuclear industry, electronics manufacturing Non-caseating granulomas in upper lobes (mimics sarcoidosis) Steroid-responsive; positive beryllium lymphocyte proliferation test (BeLPT)

4. Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)

Immunologic reaction to inhaled organic antigens (e.g., Farmer's lung from moldy hay containing Saccharopolyspora rectivirgula ; Bird fancier's lung from avian proteins).

Presentation : Acute episodes of fever, cough, and dyspnea 4-8 hours post-exposure; chronic exposure leads to upper/middle lobe pulmonary fibrosis.

Treatment : Complete avoidance of antigen exposure ± systemic corticosteroids.